Abiopharma

🔍 HAYEK JOSEPH B (Executive)

Company: WORTHINGTON ENTERPRISES, INC. (WOR)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 19,900 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: false | shares_owned_after: 230,239.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9,230 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: false | shares_owned_after: 239,469.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 4,610 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: false | shares_owned_after: 244,079.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,472 shares of Common Shares at $56.35 per share (Direct)
  Date: 2026-06-26 | Code: F | equity_swap_involved: false | shares_owned_after: 242,607.00 | transaction_form_type: 4 | Footnotes: F4
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By IRA (Merrill-Lynch) | shares_owned_after: 2,000.00
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By IRA (Vanguard) | shares_owned_after: 1,677.00 | Footnotes: F5
• Acquired 5 shares of Phantom Stock Acquired Under the Deferred Compensation Plan (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: false | shares_owned_after: 5,343.74 | transaction_form_type: 4 | Footnotes: F6, F7, F7, F8

Footnotes:

• F1: An award of restricted stock was granted pursuant to the Worthington Enterprises, Inc. 2024 Long-Term Incentive Plan. The restricted stock will vest on the third anniversary of the grant date.
• F2: An award of restricted stock was granted pursuant to the Worthington Enterprises, Inc. 2024 Long-Term Incentive Plan. The restricted stock will vest on the second anniversary of the grant date.
• F3: An award of restricted stock was granted pursuant to the Worthington Enterprises, Inc. 2024 Long-Term Incentive Plan. The restricted stock will vest on the first anniversary of the grant date.
• F4: Represents shares withheld upon the vesting of restricted stock in order to satisfy the reporting person's tax withholding obligation upon such vesting.
• F5: The amount reported includes additional common shares acquired pursuant to the dividend reinvestment feature of the IRA as reported in the plan statement dated March 31, 2026.
• F6: The theoretical WOR common shares ("phantom stock") credited to the reporting person's account in the Worthington Industries, Inc. Amended and Restated 2005 Deferred Compensation Plan for Directors, as amended (the "Plan") track WOR common shares on a one-for-one basis.
• F7: Prior to October 1, 2014, the account balances related to the phantom stock investment option could be immediately transferred to other deemed investment options under the terms of the Plan. The Plan provides that, effective October 1, 2014 and thereafter, any amount credited in a participant's account to the phantom stock fund may not be transferred to an alternative deemed investment option under the Plan until distribution from the Plan. Distributions are made only in WOR common shares and generally commence upon leaving Worthington Enterprises, Inc. and its subsidiaries.
• F8: The amount reported includes the additional unfunded theoretical common shares (i.e., phantom stock) credited pursuant to the dividend reinvestment feature of the 2005 NQ Plan on March 27, 2026.